PIK3CA and neoplasm: On the other hand, PI3K/AKT/mTOR inhibitors have immunomodulatory properties in that they can enhance tumor immune surveillance by reducing the expression of immunosuppressive cytokines and chemokines and by dampening the effector functions of immune regulatory cells like regulatory T cells or myeloid-derived suppressor cells [91,92].